Our Hyaluronan-Enhanced, Polymeric Transcatheter Aortic Valves are inspired by nature and perfected by engineers.
YoungHeartValve has 3 patents approved or pending in the US and worldwide
Lorem ipsum doler sit.
Lorem ipsum doler sit.
YoungHeartValve successfully raised double the normal amount for an NIH SBIR Phase 1
Founded by leaders in the structural heart space, we are changing the future of heart valve intervention. Our valves eliminate the need for animal tissue.
YoungHeartValve’s TAVR device incorporates hyaluronan into its leaflets, creating a proven thrombosis- and calcification-resistant biomolecular interpenetrated network.
Fully synthetic valve platform enables automated, animal-free manufacturing and scalable expansion across multiple valve indications, significantly reducing cost and capital intensity.
YHV's biopolymer leaflets are built for endurance. Testing done so far shows success rates that will last a lifetime instead of needing repeat interventions.
Balloon expansion is easier on the surrounding tissue and leaflets, which allows our biopolymer valves to fit more naturally, decreases risk, and increases patient safety and outcomes.
Our unique, patent-pending technology allows for less leakage caused by space left between natural heart tissue and the valve replacement.
In 6-month chronic animal studies (juvenile sheep), our valve demonstrated sustained biocompatibility with no calcification, no blood-clotting, and no requirement for lifelong blood thinners.
Because our biopolymer valves do not require animal tissue or time-intensive labor, the manufacturing is incredbly scalable.
